There is one research and development item that is gaining explosive popularity among both global and domestic pharmaceutical companies –obesity treatment.

The use of obesity drugs has also increased dramatically with the significant rise in the number of obese people around the world. Global sales of obesity drugs reached USD 6.68 billion (about KRW 9 trillion) last year, up 145.6% from USD 2.72 billion in 2022.

In particular, the success of glucagon-like peptide (GLP-1) receptor agonist obesity drugs such as Saxenda, Wegovy, and Zepbound has attracted the attention of domestic and foreign pharmaceutical companies to GLP-1 drug candidates. Saxenda posted sales of KRW 1.225 trillio